Health Care Supplies

Immucor, Inc. (Nasdaq: BLUD) today announced the expiration of the "go-shop" period pursuant to the terms of the previously announced merger agreement, dated as of July 2, 2011, which contemplates the acquisition of the Company by an affiliate of TPG Capital, L.P. The "go-shop" period expired at...

Shares of Immucor (NASDAQ: BLUD) are lower on the session by 0.19%, trading at $26.60. Overall call volume is now running at 4.08x the daily average, with 2% of all calls traded being purchases on the offer. 1,216 contracts have traded on the session so far. Immucor, Inc. develops, manufactures...

Immucor, Inc. (Nasdaq: BLUD) and IVD Acquisition Corporation, an affiliate of TPG Capital, L.P., today announced that Germany's Federal Cartel Office has granted clearance in connection with IVD Acquisition Corporation's previously announced transaction to acquire the Company. As announced on...

Barrington Research has upgraded Haemonetics (NYSE: HAE) from Perform to Outperform and has established a $70 price target.

Duncan Williams has raised the price target on Vascular Solutions (NASDAQ: VASC) from $15 to $17 and maintains its Buy rating.

Immucor, Inc. (Nasdaq: BLUD) and IVD Acquisition Corporation, an affiliate of TPG Capital, L.P., today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, relating to IVD Acquisition Corporation's previously announced tender...

Stocks trading at or near 52-week highs and lows provide excellent trading opportunities, as volatility tends to increase at such levels and exit/entry points become more clearly defined. The following stocks hit new 52-week highs in Monday's trading session (listed from highest total volume to...

Morgan Stanley has published a report on Haemonetics (NYSE: HAE). In the report, Morgan Stanley wrote, "Hospital sales are unlikely to show the reacceleration management was hoping for as the OrthoPAT recall cuts into growth and pulls sales force focus away from blood management. The company was...

Morgan Keegan is out with its report today on Haemonetics (NYSE: HAE), lowering its PT from $76 to $65. In its report, Morgan Keegan writes, "Although the decline in the stock appears overdone, with double-digit EPS growth not likely until the fiscal 4Q, we maintain our Market Perform rating. Our...

Morgan Keegan has lowered the price target on Haemonetics Corporation (NYSE: HAE) from $76 to $65 and maintains its Market Perform rating.

Duncan-Williams has published a research report on Vascular Solutions (NASDAQ: VASC) previewing earnings for the second quarter. In the report, Duncan-Williams wrote, "Our Q2:11 Catheters revenue estimate is $13.5 million. This represents approximately 31% growth compared to the same period last...

Benchmark has published a report on RTI Biologics (NASDAQ: RTIX) upgrading the company from Hold to Buy. In the report, Benchmark wrote, "We are upgrading RTIX shares to Buy from Hold based on stronger then anticipated earnings and our view that Spine risks are abating. RTI's performance is...

Morgan Keegan has downgraded its rating on Haemonetics Corp.(NYSE: HAE) in light of the company's current upside. According to Morgan Keegan, “We are changing our rating on Haemonetics to Market Perform from Outperform. The change in rating is driven by our view that there is greater appreciation...

Benchmark made a number of rating and price target updates in a research report published today. CryoLife (NYSE: CRY) had its rating upgraded from Hold to Buy. Its price target was maintained at $6.50. On Thursday, CRY lost 1.99% of its value to finish the day at $5.42. Expedia (NASDAQ: EXPE)...

Haemonetics Corporation (NYSE: HAE) was downgraded by Morgan Keegan from "outperform" to "market perform." HAE's shares closed at $65.18 yesterday. Haemonetics' trailing-twelve-month ROA is 8.65%. Robert W. Baird downgraded Constant Contact Inc (NASDAQ: CTCT) from “outperform” to “neutral.” CTCT's...